Although the 20% beneficial effect on mortality in the CHAMPION trial did not reach statistical significance, this trend is included in our base case.
← all excerpts
The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective.
1
—
—